secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition II Corp. (DMII)
CIK:        0002040475
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001213900-26-039986
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMIIU enters $1.4M convertible note agreement for de-SPAC financing; issues $300K interim note
--------------------------------------------------------------------------------

- Total financing commitment of $1.4M; $150K already received, $300K funded on March 30, 2026 as interim convertible note.
- Conversion at 35% discount to post-merger market value at investor's discretion; nine-month maturity.
- Proceeds used for audit, accounting, SEC, Nasdaq fees, legal costs, and transaction preparation.
- Existing sponsor non-performing; investor has right to acquire sponsor interests when legally permitted.
- Exclusivity period of six months to complete de-SPAC transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/0001213900-26-039986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2040475/000121390026039986/ea0285112-8k_drugs2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-039986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer